Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amkay ProductsBOM:544169 37 3-Year RORE % is -3.18 as of Mar. 2026. GuruFocus rates BOM:544169 with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 785 Medical Devices & Instruments companies, Amkay Products ranks worse than 50.7% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Amkay Products's 3-Year RORE % for the quarter that ended in Mar. 2026 was -3.18%.
The industry rank for Amkay Products's 3-Year RORE % or its related term are showing as below:
BOM:544169's 3-Year RORE % is ranked worse than 50.7% of 785
companies
in the Medical Devices & Instruments industry
Industry Median: -2.52
vs BOM:544169: -3.18
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Amkay Products 3-Year RORE % Related Terms
Amkay Products 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Amkay Products's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544169 vs ISRG, BDX, RMD: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Amkay Products's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amkay Products 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amkay Products's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Amkay Products's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Amkay Products (BOM:544169) has a 3-Year RORE % of -3.18 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Amkay Products and its competitors. According to the industry distribution chart, Amkay Products ranks #398 out of 785 companies in the Medical Devices & Instruments industry, placing it in the top 50.7%.
Is Amkay Products' 3-Year RORE % too high?
Amkay Products' current 3-Year RORE % is -3.18. Based on the distribution chart, Amkay Products ranks #398 out of 785 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Amkay Products has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Amkay Products' 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Amkay Products ranks #398 out of 785 companies for 3-Year RORE %. This places Amkay Products in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Amkay Products and its competitors. Amkay Products's current 3-Year RORE % is -3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amkay Products stock overvalued right now?
Amkay Products (BOM:544169) has a current 3-Year RORE % of -3.18. The current 3-Year RORE % is -3.18. Amkay Products' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Amkay Products (BOM:544169), the current 3-Year RORE % is -3.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amkay Products Ltd is a healthcare company. It manufacture, assemble & market a comprehensive portfolio of medical devices, disposables and other Healthcare Products like Face Mask, Alcohol Swabs, Lancet Needles, Nebulizer, Pulse Oximeter, surgeon cap etc. used by healthcare centers, hospitals/clinics, nursing homes etc. Additionally, engaged in branding and marketing of some of the products like Diapers, Plastic Gloves, Suction Machines etc.
37GF Score
Get the complete analysis for BOM:544169
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544169 has been successfully added to your 
